Virax Biolabs Group Ltd. Class A VRAX 深 滬
已收盤 04-02 16:00:00 美东时间
0.174
-0.024
-12.12%
華盛通- 最 高0.2096
- 今 開0.181
- 成交量 244.41万股
- 最 低 0.161
- 昨 收 0.198
- 總市值 129.17万
- 52周最高 1.20
- 市盈率 靜 --
- 換手率 32.92%
- 52周最低 0.1521
- 委 比 31.47%
- 總股本 742.34万
- 歷史最高 290.00
- 量 比 0.05
- 振 幅 24.55%
- 歷史最低 0.1521
- 每 手 1
- 風險率 0.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多What's Behind The Jump In Virax Biolabs Stock?
Shares of Virax Biolabs Group are soaring Tuesday after it secured several regulatory certifications paving the way for clinical validation.
03-31 22:38
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Apellis Pharmaceuticals (NASDAQ:APLS) shares moved upwards by 138.8% t...
03-31 20:05
Virax Biolabs Group's Subsidiary Secures ISO 13485:2016 And ISO 9001:2015 Certification For Its Quality Management System
Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved ISO 13485:2016 and ISO 9001:2015 certification for its
03-31 19:39
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Vir Biotechnology (NASDAQ:VIR) shares moved upwards by 65.0% to $12.26...
02-24 20:05
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares moved upwards by 14.1% to...
01-09 05:06
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Imunon (NASDAQ:IMNN) shares increased by 8.8% to $3.6 during Wednesday...
2025-12-25 05:05
Virax Biolabs Announces $5M Ordinary Shares Offering
Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, announced today that it has entered into
2025-12-04 02:58
快讯 | Virax Biolabs Group Limited宣布完成500万美元的私募配售。
Virax Biolabs Group Limited Announces $5 Million Private Placement
2025-12-04 02:53
Virax Biolabs Group Shares Clinical Progress, Intends To Report Clinical Data From UK PAIS Trial In 2026
Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, today highlighted key milestones,
2025-12-03 20:38
Virax Biolabs Completes Patient Recruitment For UK-Based, Multi-Centre Clinical Study Evaluating Performance Of ViraxImmune Assay In Detecting T Cell Dysfunction In PAIS, Including Long COVID, PTLD, And ME/CFS
Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases, today announced that it has
2025-11-03 21:32
